Assigned to TRUSTEES OF DARTMOUTH COLLEGE, Hanover, NH (US)
Filed by TRUSTEES OF DARTMOUTH COLLEGE, Hanover, NH (US)
Filed on May 12, 2020, as Appl. No. 16/872,419.
Application 16/872,419 is a division of application No. 15/948,303, filed on Apr. 9, 2018, granted, now 10,689,618.
Application 15/948,303 is a division of application No. 14/676,028, filed on Apr. 1, 2015, granted, now 9,938,497, issued on Apr. 10, 2018.
Application 14/676,028 is a division of application No. 13/502,978, granted, now 9,181,527, issued on Nov. 10, 2015, previously published as PCT/US2010/054846, filed on Oct. 29, 2010.
Claims priority of provisional application 61/255,980, filed on Oct. 29, 2009.
Prior Publication US 2020/0339950 A1, Oct. 29, 2020
1. A method of producing one or more compositions comprising human T cells which express a heterologous ligand binding domain or a heterologous receptor other than a T cell receptor (TCR), wherein said human T cells are derived from primary human T cells and wherein said method comprises: (i) obtaining one or more compositions comprising isolated primary human T cells, each of said compositions being comprised of primary human T cells isolated from at least one human donor; (ii) modifying the primary human T cells comprised in said one or more compositions comprising primary human T cells in order to functionally impair or reduce expression of one or more components of the TCR complex endogenously expressed by said human primary T cells; and (iii) modifying the primary human T cells in the one or more compositions comprising human T cells by introducing a nucleic acid which encodes a desired exogenous ligand binding domain or a desired exogenous receptor, wherein said exogenous ligand binding domain and exogenous receptor do not comprise a TCR and further wherein said exogenous ligand binding domain or exogenous receptor directly or indirectly mediates T cell signaling upon binding of the ligand binding domain or the exogenous receptor to a ligand expressed by a target cell; thereby producing one or more compositions comprising human T cells which express at least one desired ligand binding domain or desired receptor and further wherein one or more components of the TCR complex endogenously expressed by said human primary T cells is functionally impaired or the expression of one or more components of the TCR complex endogenously expressed by said human primary T cells is reduced.